Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
Wang
Heng-Xiang
HX
Duan
Lian-Ning
LN
Ji
Shu-Quan
SQ
Guo
Zi-Kuan
ZK
D000293:Adolescent; D018943:Anthracyclines / Q000008:administration & dosage*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D003561:Cytarabine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007938:Leukemia / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000473:pathology; D010087:Oxides / Q000494:pharmacology*; D012306:Risk; D012867:Skin / Q000187:drug effects / Q000473:pathology; D014212:Tretinoin / Q000494:pharmacology*
D018943:Anthracyclines; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D003561:Cytarabine; D014212:Tretinoin; D000077237:Arsenic Trioxide